New-generation Drug Eluting Stent vs. Bare Metal Stent in Saphenous Vein Graft - 1 Year Outcomes by a Propensity Score Ascertainment (SVG Baltic Registry)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Coronary Artery Disease
- Sponsor
- Medical University of Silesia
- Enrollment
- 792
- Locations
- 3
- Primary Endpoint
- major adverse cardiac and cerebrovascular event
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Data regarding the efficacy of the percutaneous coronary intervention (PCI) with new-designed drug-eluting stent (new-DES) vs. bare metal stent (BMS) of saphenous vein grafts (SVG) stenosis is scarce. The primary objective was to compare one-year clinical outcomes of PCI in stenosis of SVG using new-DES vs. BMS in a real-world population. We carried out a multi-center registry comparing new-DES with BMS in all consecutive patients undergoing PCI of SVG. The primary composite endpoint was major adverse cardiac and cerebrovascular events (MACCE) at 1 year.
Investigators
Wojciech Wańha
MD, PhD
Medical University of Silesia
Eligibility Criteria
Inclusion Criteria
- •patients after CABG with significant SVG stenosis referred for PCI
Exclusion Criteria
- •patients who had both types of stents implanted in the same procedure
- •patients with the old-DES
- •patients who had PCI of other vascular territories during the same procedure
Outcomes
Primary Outcomes
major adverse cardiac and cerebrovascular event
Time Frame: 1 year
Secondary Outcomes
- target lesion revascularization(1 year)
- death(1 year)
- myocardial infarction(1 year)
- target vessel revascularization(1 year)
- stroke(1 year)